Arvinas (ARVN) Liabilities and Shareholders Equity (2017 - 2026)
Arvinas' (ARVN) quarterly Liabilities and Shareholders Equity came in at $647.5 million in Q1 2026, down 35.32% year-on-year from $1.0 billion in Q1 2025, and down 9.81% quarter-over-quarter from $717.9 million in Q4 2025.
Arvinas (ARVN) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Arvinas' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $647.5 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 35.32% year-over-year to $647.5 million in Q1 2026; TTM through Mar 2026 was $3.1 billion, a 31.29% decrease from a year earlier, with the FY2025 full-year figure at $717.9 million, down 34.22% from the prior year.
- Liabilities and Shareholders Equity eased to $647.5 million in Q1 2026 per ARVN's latest filing, from $717.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q1 2022 and bottomed at $647.5 million in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2024), against an average of $1.1 billion.
- Across the five-year window, Liabilities and Shareholders Equity soared 118.47% in 2022 and sank 35.32% in 2026, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $1.3 billion in 2022, then gained by 2.82% to $1.3 billion in 2023, then dropped by 16.34% to $1.1 billion in 2024, then sank by 34.22% to $717.9 million in 2025, then decreased by 9.81% to $647.5 million in 2026.
- Per Business Quant, the three latest ARVN Liabilities and Shareholders Equity figures stand at $647.5 million (Q1 2026), $717.9 million (Q4 2025), and $844.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | 647.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 647.50 Mn |
| Dec 31, 2025 | 717.90 Mn |
| Sep 30, 2025 | 844.30 Mn |
| Jun 30, 2025 | 909.30 Mn |
| Mar 31, 2025 | 1.00 Bn |
| Dec 31, 2024 | 1.09 Bn |
| Sep 30, 2024 | 1.17 Bn |
| Jun 30, 2024 | 1.28 Bn |
| Mar 31, 2024 | 1.21 Bn |
| Dec 31, 2023 | 1.30 Bn |
| Sep 30, 2023 | 1.06 Bn |
| Jun 30, 2023 | 1.08 Bn |
| Mar 31, 2023 | 1.18 Bn |
| Dec 31, 2022 | 1.27 Bn |
| Sep 30, 2022 | 1.33 Bn |
| Jun 30, 2022 | 1.41 Bn |
| Mar 31, 2022 | 1.49 Bn |
| Dec 31, 2021 | 1.58 Bn |
| Sep 30, 2021 | 1.60 Bn |
| Jun 30, 2021 | 644.03 Mn |